Phase I Study of HSK42360 in Malignant Brain Tumors With BRAF V600 Mutation

This is a phase I, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, PK of HSK42360 when given orally in pediatric patients with active BRAF V600 mutation recurrent malignant brain tumors.

Trial Details

NCT ID
NCT07158710
Phase
PHASE1
Sponsor
Haisco Pharmaceutical Group Co., Ltd.
Status
RECRUITING
Cancer Type
Brain Cancer
Interventions
  • HSK42360
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Fuzhou, Fujian, China|26.06139,119.30611
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Changchun, Jilin, China|43.88,125.32278

Key Eligibility Criteria

  • Age ≥6 and \<18 years.
  • Karnofsky/Lansky Performance Status \>60.
  • Life expectancy ≥ 3 months.
  • Patients with recurrent malignant brain tumors confirmed by histology or cytology, who have failed standard treatment (disease progression after tr…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Brain Cancer Trials on Trialify →